Aurobindo Pharma said the US Food and Drug Administration (USFDA) has classified its subsidiary unit Eugia Pharma Specialities as Official Action Indicated (OAI) after a 2025 inspection, citing nine observations. The company expects no immediate business impact and remains committed to high-quality manufacturing. Q4 net profit rose 7.5% YoY to ₹909.8 crore; compared to ₹846 crore last year.